SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Meta Expands AI Training With Employee Activity Tracking Tools 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
BURLINGTON, Mass., March 03, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its year-end 2015 financial results on Thursday, March 10, 2016, at 4:30 p.m. ET.
The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 982-4677 for international participants, with Conference ID # 53086231. A live webcast of the conference call can also be accessed through the “Investors” tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections for knee OA annually. The company is also investigating another product candidate, FX007, a locally administered TrkA receptor antagonist for post-operative pain.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
